We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Drugstore trials

9 March 2011 By Lisa Lee

The $39 bln drugstore chain is selling its pharmacy benefits arm to hone in on retailing. CVS took the opposite tack, paying $26 bln for Caremark. That dog of a deal, which has dragged down performance and sparked an FTC inquiry, looks increasingly like it should be unwound.

This content is for Subscribers only

 

Email a friend

Please complete the form below.

Required fields *

*
*
*

(Separate multiple email addresses with commas)